Skip to main content
Pamela Reilly Contag

Pamela Reilly Contag

PhD, Chief Executive Officer, BioEclipse Therapeutics

Dr. Contag is an experienced senior executive for both public (President and CEO, Xenogen Corp., NASDAQ:XGEN), and private companies and is currently the CEO of BioEclipse Therapeutics. BioEclipse is entering a phase1, first in human clinical trial with a combination drug for therapy refractory solid tumors. In 2020 she joined the advisory board of the College of Biological Sciences at the University of Mn and is an Advisor to the Editorial board of Life Science Leader Magazine.  As CEO of BioEclipse she was named in the top 100 most intriguing entrepreneurs of 2018 by Goldman Sachs and also ranked in the top 10 of the San Francisco Bay Area’s Women-Led most Funded Life Science Companies of 2020.  While serving as CEO of Xenogen, the company twice received the R&D 100 award for achievements in Physics and Dr. Contag was named one of the "Top 25 Women in Small Business" by Fortune magazine. In 2011, Pamela was appointed by the White House to the Founding Board of the Startup America Partnership, an organization envisioned by the Case and Kauffman Foundations and The White House to identify, encourage and celebrate all entrepreneurs. Pamela was a National Director of Springboard Enterprises, a National Business Accelerator. She received her M.S. and PhD from the University of Minnesota Medical School in Microbiology and Immunology and completed her Postdoctoral Fellowship in1993 at the Stanford University School of Medicine. She has written over 60 publications and has over 40 patents issued as inventor.